Since hyperinsulinemia and increased insulin resistance promote macrovascular and microvascular complications [60], SGLT-2 inhibitors with their highly beneficial metabolic effects could be hypothesized to provide a novel treatment option also for DR. Here, SLC5A2 is linked to Insulin resistance.